BR112016020897A2 - ?determinação da agressividade de câncer, prognóstico e capacidade de reação a tratamento? - Google Patents
?determinação da agressividade de câncer, prognóstico e capacidade de reação a tratamento?Info
- Publication number
- BR112016020897A2 BR112016020897A2 BR112016020897A BR112016020897A BR112016020897A2 BR 112016020897 A2 BR112016020897 A2 BR 112016020897A2 BR 112016020897 A BR112016020897 A BR 112016020897A BR 112016020897 A BR112016020897 A BR 112016020897A BR 112016020897 A2 BR112016020897 A2 BR 112016020897A2
- Authority
- BR
- Brazil
- Prior art keywords
- metagene
- metabolism
- prognosis
- responsiveness
- determination
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
a presente invenção fornece métodos de determinação da agressividade, prognóstico e reação à terapia para cânceres específicos, que incluem a comparação dos níveis de expressão de um ou uma série de genes com expressão diferencial de um ou mais metagenes funcionais, incluindo um metagene de metabolismo de carboidratos/lipídios, um metagene de sinalização celular, um metagene de desenvolvimento celular, um metagene de crescimento celular, um metagene de segregação de cromossomos, um metagene de reprodução/recombinação de dna, um metagene do sistema imunológico, um metagene de doença metabólica, um metagene de metabolismo de ácidos nucleicos, um metagene de modificação pós-tradução, um metagene de modificação/síntese de proteína e um metagene de múltiplas redes. o método descrito no presente pode ser particularmente adequado como diagnóstico complementar para terapias de câncer.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2014900813A AU2014900813A0 (en) | 2014-03-11 | Determining cancer agressiveness, prognosis and responsiveness to treatment | |
AU2014901212A AU2014901212A0 (en) | 2014-04-03 | Determining cancer agressiveness, prognosis and responsiveness to treatment | |
AU2014904716A AU2014904716A0 (en) | 2014-11-21 | Determining cancer agressiveness, prognosis and responsiveness to treatment | |
PCT/AU2015/050096 WO2015135035A2 (en) | 2014-03-11 | 2015-03-11 | Determining cancer agressiveness, prognosis and responsiveness to treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112016020897A2 true BR112016020897A2 (pt) | 2018-01-23 |
Family
ID=54072534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016020897A BR112016020897A2 (pt) | 2014-03-11 | 2015-03-11 | ?determinação da agressividade de câncer, prognóstico e capacidade de reação a tratamento? |
Country Status (11)
Country | Link |
---|---|
US (1) | US20170107577A1 (pt) |
EP (1) | EP3119908A4 (pt) |
JP (1) | JP2017508469A (pt) |
KR (1) | KR20160132067A (pt) |
CN (1) | CN106661614A (pt) |
AU (1) | AU2015230677A1 (pt) |
BR (1) | BR112016020897A2 (pt) |
CA (1) | CA2941769A1 (pt) |
MX (1) | MX2016011612A (pt) |
SG (2) | SG11201607448PA (pt) |
WO (1) | WO2015135035A2 (pt) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HRP20240240T1 (hr) | 2008-12-09 | 2024-04-26 | F. Hoffmann - La Roche Ag | Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice |
GB201216017D0 (en) | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
CN108368553A (zh) * | 2015-11-20 | 2018-08-03 | 斯特拉斯堡大学 | 确定癌症患者的个性化治疗策略的方法 |
MA43957A (fr) * | 2016-02-01 | 2018-12-12 | Bayer Pharma AG | Biomarqueurs de copanlisib |
GB201608000D0 (en) | 2016-05-06 | 2016-06-22 | Oxford Biodynamics Ltd | Chromosome detection |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
CN107574243B (zh) * | 2016-06-30 | 2021-06-29 | 博奥生物集团有限公司 | 分子标志物、内参基因及其应用、检测试剂盒以及检测模型的构建方法 |
CN109562153A (zh) * | 2016-08-07 | 2019-04-02 | 诺华股份有限公司 | mRNA介导的免疫方法 |
US9725769B1 (en) * | 2016-10-07 | 2017-08-08 | Oncology Venture ApS | Methods for predicting drug responsiveness in cancer patients |
WO2018075823A1 (en) | 2016-10-19 | 2018-04-26 | United States Government As Represented By The Department Of Veterans Affairs | Compositions and methods for treating cancer |
WO2018152585A1 (en) * | 2017-02-23 | 2018-08-30 | The Council Of The Queensland Institute Of Medical Research | "biomarkers for diagnosing conditions" |
WO2018161081A1 (en) * | 2017-03-03 | 2018-09-07 | Board Of Regents, The University Of Texas System | Gene signatures to predict drug response in cancer |
SG11201908880WA (en) * | 2017-03-28 | 2019-10-30 | Nantomics Llc | MODELING miRNA INDUCED SILENCING IN BREAST CANCER WITH PARADIGM |
CN110494570A (zh) | 2017-03-29 | 2019-11-22 | 中美冠科生物技术(太仓)有限公司 | 确定癌症对卡仑尼替星敏感性的系统和方法 |
WO2018183762A1 (en) | 2017-03-29 | 2018-10-04 | United States Government As Represented By The Department Of Veterans Affairs | Methods and compositions for treating cancer |
US10854338B2 (en) * | 2017-03-29 | 2020-12-01 | Imaging Endpoints II LLC | Predicting breast cancer responsiveness to hormone treatment using quantitative textural analysis |
EP3606518A4 (en) * | 2017-04-01 | 2021-04-07 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER |
EP3641745A1 (en) * | 2017-06-20 | 2020-04-29 | The Institute of Cancer Research : The Royal Cancer Hospital | Methods and medical uses |
GB201709840D0 (en) | 2017-06-20 | 2017-08-02 | Inst Of Cancer Research: Royal Cancer Hospital | Methods and medical uses |
EP3647788A4 (en) * | 2017-06-30 | 2021-07-14 | National Institutes of Biomedical Innovation, Health and Nutrition | BIOMARKER FOR THE DETECTION OF COLORECTAL CANCER |
MX2020000406A (es) * | 2017-07-10 | 2020-10-01 | Univ Cornell | Tratamiento dirigido de la inestabilidad cromosómica y senalización del adn citosólico gen abajo para el tratamiento del cáncer. |
EP3695408A4 (en) * | 2017-10-02 | 2021-12-15 | The Broad Institute, Inc. | METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER |
CN107868825A (zh) * | 2017-11-21 | 2018-04-03 | 山东省千佛山医院 | 一种诊治肺腺癌的分子标记物 |
US11851712B2 (en) | 2018-03-06 | 2023-12-26 | Board Of Regents, The University Of Texas System | Replication stress response biomarkers for immunotherapy response |
JP2021522848A (ja) * | 2018-05-15 | 2021-09-02 | オンコロジー ベンチャー アーペーエス | 癌患者における薬物応答性を予測する方法 |
CN108704135A (zh) * | 2018-05-24 | 2018-10-26 | 江苏大学附属医院 | Chaf1a抑制剂在制备胃癌治疗药物中的用途 |
CN108866189B (zh) * | 2018-07-12 | 2022-03-01 | 吉林大学 | 一种喉鳞状细胞癌易感性预测试剂盒及系统 |
CN108841959B (zh) * | 2018-07-12 | 2022-03-01 | 吉林大学 | 一种口腔及头颈部恶性肿瘤易感性预测试剂盒及系统 |
CN108949984B (zh) * | 2018-07-25 | 2022-01-11 | 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) | 基因desi2在三阴乳腺癌诊断、预后评估及治疗中的应用 |
CN109593771B (zh) * | 2018-07-27 | 2022-03-29 | 四川大学华西医院 | 一种人类map2k5第1100位碱基突变基因及其检测试剂盒 |
CN110787296B (zh) * | 2018-08-01 | 2024-04-16 | 复旦大学附属肿瘤医院 | 一种用于预防或治疗胰腺癌的药物组合物及检测胰腺癌的试剂盒 |
WO2020092924A1 (en) * | 2018-11-02 | 2020-05-07 | Board Of Regents, The University Of Texas System | Combination therapy for the treatment of egfr tyrosine kinase inhibitor resistant cancer |
CN110286219A (zh) * | 2019-04-16 | 2019-09-27 | 福建师范大学 | 死亡相关蛋白激酶1在制备肾透明细胞癌术后预后评估试剂盒中的应用 |
CN111370056B (zh) * | 2019-05-22 | 2021-03-30 | 深圳思勤医疗科技有限公司 | 确定待测样本预定染色体不稳定指数的方法、系统和计算机可读介质 |
JP7352937B2 (ja) * | 2019-07-19 | 2023-09-29 | 公立大学法人福島県立医科大学 | 乳癌のサブタイプを鑑別又は分類するための鑑別マーカー遺伝子セット、方法およびキット |
WO2021168200A1 (en) * | 2020-02-19 | 2021-08-26 | United States Government As Represented By The Department Of Veterans Affairs | Identification of an egfr-bin3 pathway that actively suppresses invasion and reduces tumor size in glioblastoma |
US11919944B2 (en) | 2020-05-11 | 2024-03-05 | Augmenta Biosciences, Inc. | Antibodies for SARS-CoV-2 and uses thereof |
CN112133369B (zh) * | 2020-08-26 | 2023-09-22 | 吴安华 | 基于活性氧评估肿瘤患者预后性的系统以及药物敏感性评价与改善方法 |
CA3192695A1 (en) * | 2020-09-16 | 2022-03-24 | Novigenix Sa | Biomarkers for immune checkpoint inhibitors treatment |
CN112111575B (zh) * | 2020-09-22 | 2023-01-10 | 重庆医科大学附属第一医院 | 胰岛素样生长因子2在恶性肿瘤预后和治疗选择中的应用 |
US11906527B2 (en) | 2020-10-29 | 2024-02-20 | Ambergen, Inc. | Photocleavable mass-tags for multiplexed mass spectrometric imaging of tissues using biomolecular probes |
WO2022217060A1 (en) * | 2021-04-09 | 2022-10-13 | Cardiff Oncology, Inc. | Cancer treatment using parp inhibitors and plk1 inhibitors |
CN113292643A (zh) * | 2021-05-31 | 2021-08-24 | 南京市第二医院 | 一种肝癌肿瘤标志物及其应用 |
CN113355419B (zh) * | 2021-06-28 | 2022-02-18 | 广州中医药大学(广州中医药研究院) | 一种乳腺癌预后风险预测标志组合物及应用 |
CN113502329A (zh) * | 2021-07-12 | 2021-10-15 | 隋雨桐 | 检测腺苷受体a2b表达量的试剂在制备肺腺癌的诊断和/或预后试剂盒中的应用 |
WO2023107328A1 (en) * | 2021-12-08 | 2023-06-15 | Mayo Foundation For Medical Education And Research | Assessing and treating melanoma |
CN114540500A (zh) * | 2022-03-21 | 2022-05-27 | 深圳市陆为生物技术有限公司 | 评价乳腺癌患者整体生存的产品 |
CN115369173A (zh) * | 2022-09-23 | 2022-11-22 | 河北医科大学第三医院 | 基因标志物组合在预测膀胱尿路上皮癌预后中的应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4679149B2 (ja) * | 2002-09-30 | 2011-04-27 | オンコセラピー・サイエンス株式会社 | ヒト膵癌に関連する遺伝子およびポリペプチド |
MXPA06009545A (es) * | 2004-02-20 | 2007-03-07 | Johnson & Johnson | Pronosticos del cancer de mama. |
JP2005270093A (ja) * | 2004-02-24 | 2005-10-06 | Nippon Medical School | 乳癌の術後予後予測に関与する遺伝子 |
EP1777523A1 (en) * | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
CN101365806B (zh) * | 2005-12-01 | 2016-11-16 | 医学预后研究所 | 用于鉴定治疗反应的生物标记的方法和装置及其预测疗效的用途 |
US20080182246A1 (en) * | 2006-09-05 | 2008-07-31 | Yixin Wang | Methods of predicting distant metastasis of lymph node-negative primary breast cancer using biological pathway gene expression analysis |
EP2288727B1 (en) * | 2008-05-14 | 2013-07-10 | Genomic Health, Inc. | Predictors of patient response to treatment with egf receptor inhibitors |
WO2010076322A1 (en) * | 2008-12-30 | 2010-07-08 | Siemens Healthcare Diagnostics Inc. | Prediction of response to taxane/anthracycline-containing chemotherapy in breast cancer |
WO2010129965A1 (en) * | 2009-05-08 | 2010-11-11 | The Regents Of The University Of California | Cancer specific mitotic network |
KR101287600B1 (ko) * | 2011-01-04 | 2013-07-18 | 주식회사 젠큐릭스 | 초기유방암의 예후 예측용 유전자 및 이를 이용한 초기유방암의 예후예측 방법 |
WO2013163134A2 (en) * | 2012-04-23 | 2013-10-31 | The Trustees Of Columbia University In The City Of New York | Biomolecular events in cancer revealed by attractor metagenes |
US9863935B2 (en) * | 2012-05-08 | 2018-01-09 | H. Lee Moffitt Cancer And Research Institute, Inc. | Predictive biomarkers for CTLA-4 blockade therapy and for PD-1 blockade therapy |
-
2015
- 2015-03-11 AU AU2015230677A patent/AU2015230677A1/en not_active Abandoned
- 2015-03-11 BR BR112016020897A patent/BR112016020897A2/pt not_active Application Discontinuation
- 2015-03-11 JP JP2016556734A patent/JP2017508469A/ja active Pending
- 2015-03-11 SG SG11201607448PA patent/SG11201607448PA/en unknown
- 2015-03-11 CN CN201580024894.0A patent/CN106661614A/zh active Pending
- 2015-03-11 EP EP15761628.5A patent/EP3119908A4/en not_active Withdrawn
- 2015-03-11 KR KR1020167027926A patent/KR20160132067A/ko unknown
- 2015-03-11 WO PCT/AU2015/050096 patent/WO2015135035A2/en active Application Filing
- 2015-03-11 US US15/125,515 patent/US20170107577A1/en not_active Abandoned
- 2015-03-11 MX MX2016011612A patent/MX2016011612A/es unknown
- 2015-03-11 CA CA2941769A patent/CA2941769A1/en not_active Abandoned
- 2015-03-11 SG SG10201807838SA patent/SG10201807838SA/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2017508469A (ja) | 2017-03-30 |
AU2015230677A1 (en) | 2016-10-27 |
WO2015135035A2 (en) | 2015-09-17 |
SG10201807838SA (en) | 2018-10-30 |
MX2016011612A (es) | 2016-12-12 |
CA2941769A1 (en) | 2015-09-17 |
EP3119908A4 (en) | 2018-02-21 |
US20170107577A1 (en) | 2017-04-20 |
KR20160132067A (ko) | 2016-11-16 |
CN106661614A (zh) | 2017-05-10 |
WO2015135035A3 (en) | 2016-09-15 |
EP3119908A2 (en) | 2017-01-25 |
SG11201607448PA (en) | 2016-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016020897A2 (pt) | ?determinação da agressividade de câncer, prognóstico e capacidade de reação a tratamento? | |
Sripada et al. | hsa-miR-4485 regulates mitochondrial functions and inhibits the tumorigenicity of breast cancer cells | |
BR112018073861A2 (pt) | métodos de terapia de genes para doenças e condições relacionadas com a idade | |
GB2552267A (en) | Detection and treatment of disease exhibiting disease cell heterogeneity and systems and methods for communicating test results | |
BR122022007092B8 (pt) | Método para construir um perfil de dna, método para construir uma biblioteca de ácido nucléico, biblioteca de ácido nucléico, pluralidade de iniciadores e kit | |
SG10201906673WA (en) | Artificial nucleic acid molecules | |
Su et al. | Identification of micro RNA s involved in the radioresistance of esophageal cancer cells | |
BR112016003868A2 (pt) | método, aparelho, mídia de armazenamento não transitório, e, programa de computador | |
BR112015023394B8 (pt) | Sistema e complexo bioluminescente | |
BR112016030462A2 (pt) | moléculas de ligação, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método de produção de uma molécula de ligação, composição farmacêutica, uso da molécula de ligação, método de tratamento de doenças e de indução da lise de células alvo | |
MX2014006404A (es) | Metodos y kits para el pronostico del cancer colorrectal. | |
BR112017025254A2 (pt) | ?métodos para detecção de pelo menos uma mutação em uma pluralidade de genes relacionados ao câncer, selecionar um indivíduo para tratamento e prever a probabilidade de capacidade de resposta ao tratamento? | |
BR112014024487A2 (pt) | métodos para aumentar a eficácia da terapia baseada em cd37 | |
BR112014027905A2 (pt) | anticorpo, célula, ácido nucleico, métodos de identificação de um primeiro anticorpo, de inibição do crescimento de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína, de diagnóstico da presença de um tumor e de distribuição de agente citotóxico. | |
Fahim et al. | Inflammatory breast carcinoma: elevated microRNA miR-181b-5p and reduced miR-200b-3p, miR-200c-3p, and miR-203a-3p expression as potential biomarkers with diagnostic value | |
BR112016021679A2 (pt) | proteína de ligação ao antígeno, métodos de produção de uma proteína de ligação ao antígeno e de identificação de uma ou mais proteínas de ligação ao antígeno, hibridoma, ácido nucleico, célula, e, animal não humano geneticamente modificado. | |
EA201890649A1 (ru) | Новые биомаркеры и способы лечения рака | |
MX2019011017A (es) | Sistema para predecir el pronóstico y beneficio de una quimioterapia adyuvante para pacientes con cáncer gástrico en estadio ii y iii. | |
MX2019013953A (es) | Metodo basado en expresion genica para clasificar pacientes con cancer de riñon de acuerdo al riesgo de recurrencia. | |
EA201290107A1 (ru) | Способ определения пациента как восприимчивого или не восприимчивого к иммунотерапии | |
Zhou et al. | Decreased expression of hsa‑miR‑372 predicts poor prognosis in patients with gallbladder cancer by affecting chloride intracellular channel 1 | |
EA201491780A1 (ru) | Мутанты c-raf, придающие резистентность к ингибиторам raf | |
Jin et al. | Association between KRAS gene polymorphisms and genetic susceptibility to breast cancer in a Chinese population | |
Huang et al. | Revisiting lung cancer metastasis: insight from the functions of long non-coding RNAs | |
Marcone et al. | Proteomic signatures of radioresistance: Alteration of inflammation, angiogenesis and metabolism-related factors in radioresistant oesophageal adenocarcinoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |